PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
16267230-5	2005	Cav1 (L-type) blockers (10 microM dihydropyridines) were the only ones that significantly reduced the sAHP.	Dihydropyridines	34-50	caveolin 1	Homo sapiens	0-4
16846237-6	2006	These dihydropyridines also inhibited the efflux of the known ABCG2 substrates, mitoxantrone and pheophorbide-a, from ABCG2-overexpressing cells, and nicardipine was more potent in inhibiting this transport.	Dihydropyridines	6-22	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	62-67
16846237-6	2006	These dihydropyridines also inhibited the efflux of the known ABCG2 substrates, mitoxantrone and pheophorbide-a, from ABCG2-overexpressing cells, and nicardipine was more potent in inhibiting this transport.	Dihydropyridines	6-22	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	118-123
16846237-8	2006	In addition, nontoxic concentrations of dihydropyridines increased the sensitivity of ABCG2-expressing cells to mitoxantrone by 3-5-fold.	Dihydropyridines	40-56	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	86-91
16313901-7	2006	Thus, dihydropyridines and angiotensin converting enzyme inhibitors limit high glucose-induced superoxide formation and improve NO bioavailability in human endothelial cells, in part via bradykinin and p38MAPK.	Dihydropyridines	6-22	kininogen 1	Homo sapiens	187-197
16247709-11	2005	CONCLUSIONS: Dipyridamole and several dihydropyridines are effective BCRP inhibitors, but bepridil, diltiazem, and verapamil are not.	Dihydropyridines	38-54	ATP binding cassette subfamily G member 2	Canis lupus familiaris	69-73
15960543-2	2005	Bicycloeneamine 1 was a useful intermediate in the synthesis of pyrazolopyridine calcitonin receptor partial agonists 2a-f. Dihydropyridines 10a-c were conveniently prepared by reaction of 1 with Knoevenagel adducts 9a-c, or in the case of 10d, by a three component reaction with 1, beta-ketoester 7b, and aldehyde 8c.	Dihydropyridines	124-140	calcitonin receptor	Homo sapiens	81-100
15908473-0	2005	Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies.	Dihydropyridines	11-27	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	78-110
15908473-3	2005	The effects of 25 synthesized dihydropyridines and corresponding pyridines along with 4 commercially available dihydropyridines (niguldipine, nicardipine, nifedipine, and nitrendipine) on the intracellular accumulation of the BCRP substrate mitoxantrone were evaluated in BCRP-expressing human breast cancer MCF-7/MX100 and human non-small cell lung cancer H460/MX20 cells.	Dihydropyridines	30-46	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	226-230
15908473-3	2005	The effects of 25 synthesized dihydropyridines and corresponding pyridines along with 4 commercially available dihydropyridines (niguldipine, nicardipine, nifedipine, and nitrendipine) on the intracellular accumulation of the BCRP substrate mitoxantrone were evaluated in BCRP-expressing human breast cancer MCF-7/MX100 and human non-small cell lung cancer H460/MX20 cells.	Dihydropyridines	111-127	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	226-230
15097246-4	2004	However, increases in plasma angiotensin II in response to dihydropyridines could contribute to increases in sympathetic activity during chronic treatment.	Dihydropyridines	59-75	angiotensinogen	Homo sapiens	29-43
14993732-5	2004	We identified Phe(1112) and Ser(1115) in the pore-forming IIIS5-S6 linker region of the alpha(1C) subunit as critical determinants of the binding of dihydropyridines (DHP).	Dihydropyridines	149-165	dihydropyrimidinase	Homo sapiens	167-170
15126926-2	2004	Both noradrenaline and angiotensin II stimulate preproendothelin-1 gene expression, yet the effects of high doses of dihydropyridines on preproendothelin-1 expression in vivo remain unknown.	Dihydropyridines	117-133	endothelin 1	Rattus norvegicus	137-155
15126926-3	2004	OBJECTIVES: To investigate the effects of high doses of dihydropyridines on preproendothelin-1 expression in the ventricles and aorta of normotensive rats.	Dihydropyridines	56-72	endothelin 1	Rattus norvegicus	76-94
14645476-5	2003	The small Ca2+ current remaining in IHCs from 3-week-old CaV1.3-/- mice was mainly mediated by L-type Ca2+ channels, because it was sensitive to dihydropyridines but resistant to inhibitors of non-L-type Ca2+ channels such as omega-conotoxins GVIA and MVIIC and SNX-482.	Dihydropyridines	145-161	calcium channel, voltage-dependent, L type, alpha 1D subunit	Mus musculus	57-63
12438157-4	2002	Dihydropyridines block gastrin-induced histamine secretion.	Dihydropyridines	0-16	gastrin	Homo sapiens	23-30
12649379-5	2003	INS-1 cells expressing Ca(v)1.3/DHPi maintained glucose- and KCl-stimulated insulin secretion in the presence of DHPs, whereas cells expressing Ca(v)1.2/DHPi demonstrated DHP resistance to only KCl-induced secretion.	Dihydropyridines	113-117	insulin 1	Rattus norvegicus	0-5
12058245-8	2002	Although sildenafil and antihypertensive dihydropyridines like amlodipine are metabolized by the same cytochrome P450 enzyme, CYP3A4 in the liver, the combination of these drugs does not exhibit a synergistic blood pressure lowering action.	Dihydropyridines	41-57	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	126-132
12197745-5	2002	A synthetic application is illustrated here to stereoselectively transform the resulting dihydropyridines to cis-1-azadecalins with unique anti relative stereochemistry at C2 and C2a, leading to synthesis of epi isomers of (-)-pumiliotoxin C.	Dihydropyridines	89-105	cytokine inducible SH2 containing protein	Homo sapiens	109-114
12123058-1	2002	Pyridine and bis(TMS)ketene acetals (TMS = trimethylsilyl) react successively with methylchloroformate and iodine (or peracids) to give, via functionalized dihydropyridines, bicyclic nitrogen-containing lactones which have been characterized by X-ray crystallography.	Dihydropyridines	156-172	PYD and CARD domain containing	Homo sapiens	17-20
12123058-1	2002	Pyridine and bis(TMS)ketene acetals (TMS = trimethylsilyl) react successively with methylchloroformate and iodine (or peracids) to give, via functionalized dihydropyridines, bicyclic nitrogen-containing lactones which have been characterized by X-ray crystallography.	Dihydropyridines	156-172	PYD and CARD domain containing	Homo sapiens	37-40
11487617-0	2001	Neuronal Ca(V)1.3alpha(1) L-type channels activate at relatively hyperpolarized membrane potentials and are incompletely inhibited by dihydropyridines.	Dihydropyridines	134-150	caveolin 1	Homo sapiens	9-15
11487504-1	2001	Inhibition of Ca(v)1.2 by antagonist 1,4 dihydropyridines (DHPs) is associated with a drug-induced acceleration of the calcium (Ca(2+)) channel current decay.	Dihydropyridines	59-63	calcium channel, voltage-dependent, L type, alpha 1C subunit S homeolog	Xenopus laevis	14-22
11325018-1	2001	Using a whole-cell patch-clamp technique, state-dependent inhibition of dihydropyridines (DHP)s was investigated on L-type channels in A7r5 cells.	Dihydropyridines	72-88	dihydropyrimidinase	Rattus norvegicus	90-93
11278630-1	2001	We investigated the mechanism of interaction of individual L-type channel amino acid residues with dihydropyridines within a dihydropyridine-sensitive alpha1A subunit (alpha1A(DHP)).	Dihydropyridines	99-115	dihydropyrimidinase L homeolog	Xenopus laevis	176-179
10791962-12	2000	Resistance to dihydropyridines, calciseptine, MVIIC, and kurtoxin indicates that Ca(V)1, Ca(V)2.1, and Ca(V)3 (L-, P/Q-, and T-type) channels contribute little to this evoked response.	Dihydropyridines	14-30	caveolin 1, caveolae protein	Mus musculus	81-87
10791962-12	2000	Resistance to dihydropyridines, calciseptine, MVIIC, and kurtoxin indicates that Ca(V)1, Ca(V)2.1, and Ca(V)3 (L-, P/Q-, and T-type) channels contribute little to this evoked response.	Dihydropyridines	14-30	caveolin 3	Mus musculus	103-109
10644905-1	2000	Gingival hyperplasia, a well-known side effect of ciclosporin A (CS-A), is much more prominent when CS-A is used in combination with calcium channel blockers, especially dihydropyridines.	Dihydropyridines	170-186	chorionic somatomammotropin hormone 1	Homo sapiens	50-63
10835047-1	2000	Dihydropyridines (DHPs) are widely used antihypertensive drugs and inhibit excitation-contraction (E-C) coupling in vascular smooth muscle and in myocardial cells by antagonizing L-type Ca2+ channels (DHP receptors).	Dihydropyridines	0-16	dihydropyrimidinase	Homo sapiens	18-21
10835047-10	2000	Based on the specific mechanism of the skeletal muscle E-C coupling, we propose the stabilization of a conformational state of the DHP receptor by DHPs, which is sufficient to activate the ryanodine receptor.	Dihydropyridines	147-151	dihydropyrimidinase	Homo sapiens	131-134
10725264-9	2000	In contrast, cytokine-induced mRNA expression of monocyte chemoattractant protein 1 (MCP-1) in these cells was down-regulated by more than 60% in the presence of both dihydropyridines, as judged by RT - PCR and Northern blot analyses.	Dihydropyridines	167-183	chemokine (C-C motif) ligand 2	Mus musculus	49-83
10725264-9	2000	In contrast, cytokine-induced mRNA expression of monocyte chemoattractant protein 1 (MCP-1) in these cells was down-regulated by more than 60% in the presence of both dihydropyridines, as judged by RT - PCR and Northern blot analyses.	Dihydropyridines	167-183	chemokine (C-C motif) ligand 2	Mus musculus	85-90
10644905-1	2000	Gingival hyperplasia, a well-known side effect of ciclosporin A (CS-A), is much more prominent when CS-A is used in combination with calcium channel blockers, especially dihydropyridines.	Dihydropyridines	170-186	chorionic somatomammotropin hormone 1	Homo sapiens	65-69
10644905-1	2000	Gingival hyperplasia, a well-known side effect of ciclosporin A (CS-A), is much more prominent when CS-A is used in combination with calcium channel blockers, especially dihydropyridines.	Dihydropyridines	170-186	chorionic somatomammotropin hormone 1	Homo sapiens	100-104
10703877-0	1999	Comparative effects of different dihydropyridines on the expression of adhesion molecules induced by TNF-alpha on endothelial cells.	Dihydropyridines	33-49	tumor necrosis factor	Homo sapiens	101-110
10579843-3	1999	We have previously disclosed dihydropyridines such as 1a,b as selective alpha(1a) antagonists as a potential treatment for benign prostatic hyperplasia (BPH).	Dihydropyridines	29-45	calcium voltage-gated channel subunit alpha1 A	Homo sapiens	72-80
9950957-12	1999	Our study shows that AT1 and V1 receptors stimulate [Ca2+]i by a common mechanism characterized by preferential action on voltage-gated L-type channels sensitive to dihydropyridines.	Dihydropyridines	165-181	angiotensin II receptor, type 1a	Rattus norvegicus	21-24
10336541-1	1999	We investigated block of the alpha1Cb subunit of L-type calcium channels by dihydropyridines (DHPs) in which a permanently charged or neutral head group was linked to the active DHP moiety by a spacer chain containing ten methylene (-CH2) groups.	Dihydropyridines	76-92	dihydropyrimidinase	Homo sapiens	94-97
10226093-1	1999	BACKGROUND: Calcium channel blockers (CCB) of all subclasses: the dihydropyridines, benzothiazepines, and phenylalkylamines, at nanomolar concentrations, have been shown to up-regulate interleukin-6 (IL-6) mRNA.	Dihydropyridines	66-82	interleukin 6	Homo sapiens	185-198
10226093-1	1999	BACKGROUND: Calcium channel blockers (CCB) of all subclasses: the dihydropyridines, benzothiazepines, and phenylalkylamines, at nanomolar concentrations, have been shown to up-regulate interleukin-6 (IL-6) mRNA.	Dihydropyridines	66-82	interleukin 6	Homo sapiens	200-204
9380037-1	1997	To elucidate the mechanism underlying the interaction between the L-type Ca2+ channel and the dihydropyridines (DHPs), contribution of the repeat III was studied by constructing chimeras between the DHP-sensitive alpha1C and DHP-insensitive alpha1E subunits.	Dihydropyridines	94-110	dihydropyrimidinase	Homo sapiens	112-115
9049538-3	1997	Vascularly selective dihydropyridines usually elicit increases in heart rate, sympathetic counterregulation and renin release in the short term.	Dihydropyridines	21-37	renin	Homo sapiens	112-117
9186066-3	1997	As a consequence, reflex tachycardia, increased cardiac output, and increased plasma catecholamine and plasma renin activity are commonly seen, particularly with the initial dose and with short-acting dihydropyridines.	Dihydropyridines	201-217	renin	Homo sapiens	110-115
9275710-5	1996	These results indicate that m-Nif prevented and regressed cardiac mass in DOCA hypertensive rats through mechanisms that may be associated with their density of DHP binding sites and control of blood pressure.	Dihydropyridines	161-164	zinc finger protein 335	Rattus norvegicus	30-33
8832591-0	1996	Modulation of kappa-opioid receptor mediated tolerance in the guinea-pig ileum by chronic co-administration of dihydropyridines.	Dihydropyridines	111-127	kappa-type opioid receptor	Cavia porcellus	14-35
8740241-5	1996	It is suggested that the endothelium modulates vascular relaxation to dihydropyridines by an enhancement of calcium antagonist actions by basally released EDRF/NO at the level of vascular smooth muscles or by a dihydropyridine-induced increase in the release of EDRF/NO.	Dihydropyridines	70-86	alpha hemoglobin stabilizing protein	Homo sapiens	155-159
8740241-5	1996	It is suggested that the endothelium modulates vascular relaxation to dihydropyridines by an enhancement of calcium antagonist actions by basally released EDRF/NO at the level of vascular smooth muscles or by a dihydropyridine-induced increase in the release of EDRF/NO.	Dihydropyridines	70-86	alpha hemoglobin stabilizing protein	Homo sapiens	262-266
8845091-8	1995	Angiotensin converting enzyme inhibitors, alpha-adrenergic blockers, and dihydropyridines appear to improve insulin sensitivity.	Dihydropyridines	73-89	insulin	Homo sapiens	108-115
8770786-0	1995	The dihydropyridines modulate neurotensin inotropic action paradoxically.	Dihydropyridines	4-20	neurotensin/neuromedin N	Cavia porcellus	30-41
7946179-9	1994	Treatment with the dihydropyridines inhibited platelet aggregability, shifting the beta-TG curve toward lower values.	Dihydropyridines	19-35	pro-platelet basic protein	Homo sapiens	83-90
7472417-3	1995	ICa in A-2 cells was sensitive to dihydropyridines and omega CTX MVIIC, less so to omega CgTX GVIA and insensitive to omega Aga IVa.	Dihydropyridines	34-50	inhibitor of carbonic anhydrase	Mus musculus	0-3
7515982-4	1994	These data indicate that in aortic fibroblasts stimulated by bFGF, L-type calcium channels participate in the antimitotic effect of dihydropyridines and suggest the existence of interactions between these channels and the bFGF signaling pathways.	Dihydropyridines	132-148	fibroblast growth factor 2	Rattus norvegicus	61-65
8126383-7	1994	In conclusion, the evidence suggests that dihydropyridines inhibit PGE2 production in amnion cells by directly inhibiting PLA2 rather than its actions on calcium channels.	Dihydropyridines	42-58	phospholipase A2 group IB	Homo sapiens	122-126
8205303-6	1994	Plasma levels of beta-thromboglobulin (beta-TG) and platelet aggregation induced by serotonin were measured six times during 24 h. Both dihydropyridines significantly lowered systolic and diastolic blood pressure.	Dihydropyridines	136-152	pro-platelet basic protein	Homo sapiens	17-37
8205303-6	1994	Plasma levels of beta-thromboglobulin (beta-TG) and platelet aggregation induced by serotonin were measured six times during 24 h. Both dihydropyridines significantly lowered systolic and diastolic blood pressure.	Dihydropyridines	136-152	pro-platelet basic protein	Homo sapiens	39-46
8394721-5	1993	Unlike alpha 1C, alpha 1A channels are largely insensitive to dihydropyridines and FPL 64176, but respond to the cone snail peptide omega-CTx-MVIIC(SNX-230), a potent and fairly selective inhibitor.	Dihydropyridines	62-78	calcium voltage-gated channel subunit alpha1 A	Homo sapiens	17-25
1364181-3	1992	Dihydropyridine calcium antagonists are associated with an excess incidence of coronary events, whereas non-dihydropyridines prevent reinfarction provided left ventricular (LV) function is adequate; dihydropyridines tend to increase heart rate and stimulate the sympathetic and renin-angiotensin systems.	Dihydropyridines	199-215	renin	Homo sapiens	278-283
1504758-12	1992	17 beta-Oestradiol (10 and 30 microM) decreased the peak inward Ca2+ current (ICa), which was sensitive to [Ca2+]o, dihydropyridines and isoprenaline, to 59 +/- 3% and 39 +/- 5% (n = 7 approximately 9, P less than 0.01) respectively, without producing any significant change in the shape of the current-voltage relationship.5.	Dihydropyridines	116-132	LOW QUALITY PROTEIN: carbonic anhydrase 2	Cavia porcellus	64-67
1649768-6	1991	These results indicate that dihydropyridines can enhance synaptic efficacy in the CA1 region of the hippocampus.	Dihydropyridines	28-44	carbonic anhydrase 1	Homo sapiens	82-85
2015041-7	1991	The potentiation effects by these dihydropyridines of VCR and VP16 on KB or KB/VM-4 cells also appeared to be due to enhanced accumulation of radioactive VP16 or VCR, but the effects might be mediated through other mechanisms, plausibly enhanced cellular uptake of the drugs.	Dihydropyridines	34-50	host cell factor C1	Homo sapiens	62-66
2015041-7	1991	The potentiation effects by these dihydropyridines of VCR and VP16 on KB or KB/VM-4 cells also appeared to be due to enhanced accumulation of radioactive VP16 or VCR, but the effects might be mediated through other mechanisms, plausibly enhanced cellular uptake of the drugs.	Dihydropyridines	34-50	host cell factor C1	Homo sapiens	154-158
1718862-7	1991	Ca++ influx through voltage-activated channels in cultured cortical astrocytes can substantially increase [Ca++]i and these channels can be dynamically modulated by dihydropyridines.	Dihydropyridines	165-181	carbonic anhydrase 1	Mus musculus	107-113
2145465-6	1990	The restorative effects of external Ca2+ after pretreatment with Ca2(+)-antagonists were significantly less strong after pretreatment with 1,4-dihydropyridine than with non-dihydropyridines in papillary muscle strips.	Dihydropyridines	173-189	carbonic anhydrase 2	Homo sapiens	36-39
2260156-10	1990	To investigate the critical period over which dihydropyridines might be effective, their action at the earlier time point of 4 hours was tested where a significant induction of ornithine decarboxylase occurs (60 pmol/mg/hr).	Dihydropyridines	46-62	ornithine decarboxylase 1	Rattus norvegicus	177-200
1704273-6	1990	Similar interactions between the adenosine compounds and the dihydropyridines were also displayed in studies on spontaneous epileptiform activity in the CA3 region.	Dihydropyridines	61-77	carbonic anhydrase 3	Rattus norvegicus	153-156
2145465-6	1990	The restorative effects of external Ca2+ after pretreatment with Ca2(+)-antagonists were significantly less strong after pretreatment with 1,4-dihydropyridine than with non-dihydropyridines in papillary muscle strips.	Dihydropyridines	173-189	carbonic anhydrase 2	Homo sapiens	65-68
2344359-0	1990	Mechanism-based inactivation of monoamine oxidases A and B by tetrahydropyridines and dihydropyridines.	Dihydropyridines	86-102	monoamine oxidase A	Homo sapiens	32-58
1696149-9	1990	In contrast, the dihydropyridines were more effective as antagonists of Ca2+ than of Bay K 8644.	Dihydropyridines	17-33	carbonic anhydrase 2	Rattus norvegicus	72-75
33944777-6	2021	The Cryo-EM structure showed that SARM1 was locked into an inactive conformation by the inhibitor, uncovering a potential neuroprotective mechanism of dihydropyridines.	Dihydropyridines	151-167	sterile alpha and HEAT/Armadillo motif containing 1	Mus musculus	34-39
2131820-7	1990	These results are interpreted in terms of an electron/proton/electron transfer mechanism previously postulated for the oxidation of other dihydropyridines by cytochrome P-450 enzymes and model one-electron acceptors and argue against a mechanism involving hydrogen atom abstraction from nifedipine.	Dihydropyridines	138-154	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	158-174
35609238-4	2022	The capillary columns prepared with these two functional beta-CD COFs separated chiral dihydropyridines and fluoroquinolones with excellent selectivity and repeatability in capillary electrochromatography, while beta-CD COFBPDA-modified capillary columns did not present the chiral recognition ability for these drugs.	Dihydropyridines	87-103	ACD shelterin complex subunit and telomerase recruitment factor	Homo sapiens	212-219
33233858-2	2020	However, common medications like dihydropyridines (DHPs), a kind of classic calcium channel blocker, have poor selectivity to hCav1.3 in clinical treatment, mainly due to being implicated in cardiovascular side-effects mediated by human Cav1.2 (hCav1.2).	Dihydropyridines	33-49	calcium voltage-gated channel subunit alpha1 D	Homo sapiens	126-133
33233858-2	2020	However, common medications like dihydropyridines (DHPs), a kind of classic calcium channel blocker, have poor selectivity to hCav1.3 in clinical treatment, mainly due to being implicated in cardiovascular side-effects mediated by human Cav1.2 (hCav1.2).	Dihydropyridines	33-49	calcium voltage-gated channel subunit alpha1 C	Homo sapiens	237-243
33233858-2	2020	However, common medications like dihydropyridines (DHPs), a kind of classic calcium channel blocker, have poor selectivity to hCav1.3 in clinical treatment, mainly due to being implicated in cardiovascular side-effects mediated by human Cav1.2 (hCav1.2).	Dihydropyridines	33-49	calcium voltage-gated channel subunit alpha1 C	Homo sapiens	245-252
33233858-2	2020	However, common medications like dihydropyridines (DHPs), a kind of classic calcium channel blocker, have poor selectivity to hCav1.3 in clinical treatment, mainly due to being implicated in cardiovascular side-effects mediated by human Cav1.2 (hCav1.2).	Dihydropyridines	51-55	calcium voltage-gated channel subunit alpha1 D	Homo sapiens	126-133
33233858-2	2020	However, common medications like dihydropyridines (DHPs), a kind of classic calcium channel blocker, have poor selectivity to hCav1.3 in clinical treatment, mainly due to being implicated in cardiovascular side-effects mediated by human Cav1.2 (hCav1.2).	Dihydropyridines	51-55	calcium voltage-gated channel subunit alpha1 C	Homo sapiens	237-243
33233858-2	2020	However, common medications like dihydropyridines (DHPs), a kind of classic calcium channel blocker, have poor selectivity to hCav1.3 in clinical treatment, mainly due to being implicated in cardiovascular side-effects mediated by human Cav1.2 (hCav1.2).	Dihydropyridines	51-55	calcium voltage-gated channel subunit alpha1 C	Homo sapiens	245-252
2482456-0	1989	Thyroliberin and dihydropyridines modulate prolactin gene expression through interacting pathways in GH3 cells.	Dihydropyridines	17-33	prolactin	Rattus norvegicus	43-52
2770052-12	1989	These results suggest that, at least in part, the potentiation of epinephrine-induced hyperglycemia by dihydropyridines, non-dihydropyridines and hydralazine is related to the inhibition of peripheral glucose utilization produced by insulin.	Dihydropyridines	103-119	insulin	Homo sapiens	233-240
2825687-1	1987	The concentrations of the dihydropyridines, CD-349, nicardipine, and nimodipine, producing 50% inhibition of Ca2+, calmodulin (CaM)-dependent cyclic nucleotide phosphodiesterase (CaPDE) from rabbit aorta in the absence of Ca2+-CaM complex were approximately 7 to 13-fold higher than these of aorta CaPDE in the presence of Ca2+-CaM complex and of the trypsin treated enzyme form.	Dihydropyridines	26-42	calmodulin	Oryctolagus cuniculus	115-125
3221879-2	1988	The experiments described here were designed to test whether differences in PRL synthesis caused by the dihydropyridines are due to changes in PRL mRNA levels, whether structurally different classes of calcium channel blockers alter PRL production, and whether long term treatment with calcium channel agonists and antagonists alters intracellular free calcium, [Ca2+]i.	Dihydropyridines	104-120	prolactin	Homo sapiens	76-79
3221879-4	1988	Two calcium channel blockers which act at different sites on L-type channels than the dihydropyridines also inhibited PRL synthesis without affecting GH; 5 microM verapamil reduced PRL by 64% and 15 microM diltiazem by 89%.	Dihydropyridines	86-102	prolactin	Homo sapiens	118-121
3207701-7	1988	The results support the hypothesis that cytochrome P-450 catalyzes the oxidation of dihydropyridines to radical cations and show that the radical cations decay to nonradical products by multiple, substituent-dependent, mechanisms.	Dihydropyridines	84-100	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	40-56
2825687-1	1987	The concentrations of the dihydropyridines, CD-349, nicardipine, and nimodipine, producing 50% inhibition of Ca2+, calmodulin (CaM)-dependent cyclic nucleotide phosphodiesterase (CaPDE) from rabbit aorta in the absence of Ca2+-CaM complex were approximately 7 to 13-fold higher than these of aorta CaPDE in the presence of Ca2+-CaM complex and of the trypsin treated enzyme form.	Dihydropyridines	26-42	calmodulin	Oryctolagus cuniculus	127-130
2825687-1	1987	The concentrations of the dihydropyridines, CD-349, nicardipine, and nimodipine, producing 50% inhibition of Ca2+, calmodulin (CaM)-dependent cyclic nucleotide phosphodiesterase (CaPDE) from rabbit aorta in the absence of Ca2+-CaM complex were approximately 7 to 13-fold higher than these of aorta CaPDE in the presence of Ca2+-CaM complex and of the trypsin treated enzyme form.	Dihydropyridines	26-42	calmodulin	Oryctolagus cuniculus	227-230
2825687-1	1987	The concentrations of the dihydropyridines, CD-349, nicardipine, and nimodipine, producing 50% inhibition of Ca2+, calmodulin (CaM)-dependent cyclic nucleotide phosphodiesterase (CaPDE) from rabbit aorta in the absence of Ca2+-CaM complex were approximately 7 to 13-fold higher than these of aorta CaPDE in the presence of Ca2+-CaM complex and of the trypsin treated enzyme form.	Dihydropyridines	26-42	calmodulin	Oryctolagus cuniculus	227-230
2825687-3	1987	Kinetic analysis revealed that these dihydropyridines inhibited the activities of CaPDEs from both the aorta and brain, competitively with cyclic GMP as substrate, and the Ki values of CD-349 for CaPDE from aorta or brain in the absence or presence of Ca2+-CaM complex and trypsin-treated enzyme were 9.6, 0.75, 0.75 or 0.69, 0.70, 0.66 microM, respectively.	Dihydropyridines	37-53	calmodulin	Oryctolagus cuniculus	257-260
2408616-5	1985	We propose that these excitatory and inhibitory dihydropyridine receptor subtypes mediate contraction and relaxation, respectively, by dihydropyridines.	Dihydropyridines	135-151	calcium voltage-gated channel subunit alpha1 S	Homo sapiens	48-72
2468881-5	1988	Finally, stimulation of renin release and the consequent generation of angiotensin II are facilitated by dihydropyridines, and this increased generation of angiotensin II can be blocked by ACE inhibition.	Dihydropyridines	105-121	angiotensinogen	Homo sapiens	71-85
2468881-5	1988	Finally, stimulation of renin release and the consequent generation of angiotensin II are facilitated by dihydropyridines, and this increased generation of angiotensin II can be blocked by ACE inhibition.	Dihydropyridines	105-121	angiotensinogen	Homo sapiens	156-170
2468881-5	1988	Finally, stimulation of renin release and the consequent generation of angiotensin II are facilitated by dihydropyridines, and this increased generation of angiotensin II can be blocked by ACE inhibition.	Dihydropyridines	105-121	angiotensin I converting enzyme	Homo sapiens	189-192
2442519-7	1987	Similarities between the binding of dihydropyridines to the calcium channel and to these calcium-binding proteins have led us to suggest that a "calmodulin-like" calcium-binding protein on the calcium channel is the actual pharmacological receptor for dihydropyridine calcium channel antagonists.	Dihydropyridines	36-52	calmodulin 1	Homo sapiens	145-155
2433638-0	1986	Effects of Bay K 8644 and other dihydropyridines on basal and potassium-evoked output of MSH from mouse melanotrophs in vitro.	Dihydropyridines	32-48	msh homeobox 1	Mus musculus	89-92
6865927-2	1983	Equilibrium dialysis was used to test the ability of the dihydropyridines nitrendipine, felodipine, and nicardipine to inhibit the binding of [3H]chlorpromazine, [14C]pimozide, and 45Ca2+ to calmodulin.	Dihydropyridines	57-73	calmodulin 1	Rattus norvegicus	191-201
6548915-8	1984	These data suggest that dihydropyridines inhibit the phosphorylation of smooth muscle myosin light chains in vitro by binding to Ca2+/calmodulin and inhibiting the activation of myosin light chain kinase.	Dihydropyridines	24-40	myosin light chain kinase, smooth muscle	Meleagris gallopavo	178-203
6865927-4	1983	Equilibrium dialysis was also used to determine the ability of the dihydropyridines to interact directly with calmodulin.	Dihydropyridines	67-83	calmodulin 1	Rattus norvegicus	110-120
6870842-0	1983	N-alkylation of the haem moiety of cytochrome P-450 caused by substituted dihydropyridines.	Dihydropyridines	74-90	cytochrome P450, family 2, subfamily g, polypeptide 1	Rattus norvegicus	35-51
6897045-0	1982	Inactivation of cytochrome P-450 and production of N-alkylated porphyrins caused in isolated hepatocytes by substituted dihydropyridines.	Dihydropyridines	120-136	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	16-32
620069-1	1978	Dihydrodesmosine and dihydroisodemosine are dihydropyridines which are believed to be the immediate biosynthetic precursors of desmosine and isodesmosine, the stable pyridinium ion crosslinks of elastin.	Dihydropyridines	44-60	elastin	Homo sapiens	195-202
27556947-5	2016	Here we present crystallographic and functional analyses of drug binding to the bacterial homotetrameric model CaV channel CaVAb, which is inhibited by dihydropyridines and phenylalkylamines with nanomolar affinity in a state-dependent manner.	Dihydropyridines	152-168	caveolin 2	Homo sapiens	111-114
32787518-1	2020	OBJECTIVE: Calcium channel blockers, such as dihydropyridines, are commonly used to inhibit enhanced activity of vascular CaV1.2 channels in hypertension.	Dihydropyridines	45-61	calcium voltage-gated channel subunit alpha1 C	Homo sapiens	122-128
29930942-0	2018	Dihydropyridines Allosterically Modulate Hsp90 Providing a Novel Mechanism for Heat Shock Protein Co-induction and Neuroprotection.	Dihydropyridines	0-16	heat shock protein 86, pseudogene 1	Mus musculus	41-46
27826740-6	2016	This manuscript reviews the current information about the use of dihydropyridines as therapy for Parkinson"s disease and discusses the possible mechanism of action of these drugs, highlighting CaV1.3 calcium channels as a potential therapeutic target for neuroprotection in Parkinson"s disease.	Dihydropyridines	65-81	calcium voltage-gated channel subunit alpha1 D	Homo sapiens	193-199
27556947-10	2016	Our results define the structural basis for binding of dihydropyridines and phenylalkylamines at their distinct receptor sites on CaV channels and offer key insights into their fundamental mechanisms of action and differential therapeutic uses in cardiovascular diseases.	Dihydropyridines	55-71	caveolin 2	Homo sapiens	130-133
26748479-10	2016	Among CCB users, the use of dihydropyridines was independently associated with higher PTH (beta = +5.0 pg/mL, p < 0.0001), whereas non-dihydropyridine use was not (beta = +0.58 pg/mL, p = 0.68).	Dihydropyridines	28-44	parathyroid hormone	Homo sapiens	86-89
26663724-4	2016	Dihydropyridines (1,4-DHPs) are prospective compounds from this point of view.	Dihydropyridines	0-16	deoxyhypusine synthase	Homo sapiens	22-26
27725386-8	2016	Nifedipine (dihydropyridines) enhanced the CaSR-mediated increase in [Ca2+]cyt in IPAH-PASMCs, but not in PASMCs from normal subjects.	Dihydropyridines	12-28	calcium sensing receptor	Homo sapiens	43-47
27725386-9	2016	Nicardipine (dihydropyridines) and Bay K 8644 (a dihydropyridine Ca2+ channel activator) also augmented the CaSR-mediated [Ca2+]cyt increase in IPAH-PASMCs.	Dihydropyridines	13-29	calcium sensing receptor	Homo sapiens	108-112
25257666-5	2014	We identified several FXR-active structural classes including anthracyclines, benzimidazoles, dihydropyridines, pyrethroids, retinoic acids, and vinca alkaloids.	Dihydropyridines	94-110	nuclear receptor subfamily 1 group H member 4	Homo sapiens	22-25
26159251-2	2015	Echavarren"s gold(I) catalyst promoted the formation of pyrrole derivatives whereas the combination of PPh3AuCl and AgSbF6 afforded dihydropyridines.	Dihydropyridines	132-148	caveolin 1	Homo sapiens	103-107
24291533-7	2014	Finally, the possibility that dihydropyridines act as unintended pharmacoperones of CaSR is proposed.	Dihydropyridines	30-46	calcium sensing receptor	Homo sapiens	84-88
24683526-3	2014	Four of the 10 known alpha1 subunits (Cav1.1-Cav1.4) form the pore of L-type calcium channels (LTCCs) and contain the high-affinity drug-binding sites for dihydropyridines and other chemical classes of organic CCBs.	Dihydropyridines	155-171	calcium voltage-gated channel subunit alpha1 S	Homo sapiens	38-44
24754640-0	2014	New 5-unsubstituted dihydropyridines with improved CaV1.3 selectivity as potential neuroprotective agents against ischemic injury.	Dihydropyridines	20-36	calcium voltage-gated channel subunit alpha1 D	Homo sapiens	51-57
24683526-3	2014	Four of the 10 known alpha1 subunits (Cav1.1-Cav1.4) form the pore of L-type calcium channels (LTCCs) and contain the high-affinity drug-binding sites for dihydropyridines and other chemical classes of organic CCBs.	Dihydropyridines	155-171	calcium voltage-gated channel subunit alpha1 F	Homo sapiens	45-51
23380174-2	2013	A variety of dihydropyridines were prepared by using this green methodology in good yields and montmorillonite K-10 was found to be an inexpensive and reusable catalyst.	Dihydropyridines	13-29	keratin 10	Homo sapiens	111-115
24251620-5	2014	Other dihydropyridines inhibited TRPM3 channels.	Dihydropyridines	6-22	transient receptor potential cation channel subfamily M member 3	Homo sapiens	33-38
23300272-4	2013	Here, we report that the dihydropyridines (eg, nifedipine) increase [Ca(2+)](cyt) by activating CaSR in PASMC from IPAH patients (in which CaSR is upregulated), but not in normal PASMC.	Dihydropyridines	25-41	calcium sensing receptor	Homo sapiens	96-100
23300272-4	2013	Here, we report that the dihydropyridines (eg, nifedipine) increase [Ca(2+)](cyt) by activating CaSR in PASMC from IPAH patients (in which CaSR is upregulated), but not in normal PASMC.	Dihydropyridines	25-41	calcium sensing receptor	Homo sapiens	139-143
23300272-7	2013	Other dihydropyridines, nicardipine and Bay K8644, had similar augmenting effects on the CaSR-mediated increase in [Ca(2+)](cyt) in IPAH-PASMC; however, the nondihydropyridine blockers, such as diltiazem and verapamil, had no effect on the CaSR-mediated rise in [Ca(2+)](cyt).	Dihydropyridines	6-22	calcium sensing receptor	Homo sapiens	89-93
21910984-1	2011	The binding site within the L-type Ca(2+) channel Ca(v)1.2 for neutral dihydropyridines is well characterized.	Dihydropyridines	71-87	immunoglobulin lambda variable 2-8	Homo sapiens	50-58
21170472-0	2011	Selective antihypertensive dihydropyridines lower Abeta accumulation by targeting both the production and the clearance of Abeta across the blood-brain barrier.	Dihydropyridines	27-43	histocompatibility 2, class II antigen A, beta 1	Mus musculus	50-55
21170472-0	2011	Selective antihypertensive dihydropyridines lower Abeta accumulation by targeting both the production and the clearance of Abeta across the blood-brain barrier.	Dihydropyridines	27-43	histocompatibility 2, class II antigen A, beta 1	Mus musculus	123-128
21058008-0	2011	Comparative study on antioxidant effects and vascular matrix metalloproteinase-2 downregulation by dihydropyridines in renovascular hypertension.	Dihydropyridines	99-115	matrix metallopeptidase 2	Rattus norvegicus	54-80
21298073-6	2011	Among antihypertensive drugs, only dihydropyridines were effective in blocking and reversing the ET-1 contractile response.	Dihydropyridines	35-51	endothelin 1	Homo sapiens	97-101
21298073-12	2011	Only dihydropyridines, which partially relax uterine artery previously contracted with ET-1, might offer interesting perspectives to improve placental perfusion.	Dihydropyridines	5-21	endothelin 1	Homo sapiens	87-91
21054386-2	2011	Using immunocytochemical and electrophysiological techniques in mice lacking the Cav1.3alpha1 subunit (Cav1.3(-/-) ) or the high sensitivity of Cav1.2alpha1 subunits to dihydropyridines, Cav1.2 and Cav1.3 channels were identified as the only Cav1 channel subtypes expressed in mouse chromaffin cells.	Dihydropyridines	169-185	caveolin 1, caveolae protein	Mus musculus	144-156
21054386-2	2011	Using immunocytochemical and electrophysiological techniques in mice lacking the Cav1.3alpha1 subunit (Cav1.3(-/-) ) or the high sensitivity of Cav1.2alpha1 subunits to dihydropyridines, Cav1.2 and Cav1.3 channels were identified as the only Cav1 channel subtypes expressed in mouse chromaffin cells.	Dihydropyridines	169-185	calcium channel, voltage-dependent, L type, alpha 1C subunit	Mus musculus	144-150
21058008-11	2011	All dihydropyridines attenuated the increases in aortic MMP-2 levels and activity associated with 2K1C hypertension.	Dihydropyridines	4-20	matrix metallopeptidase 2	Rattus norvegicus	56-61
20408553-0	2010	Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines.	Dihydropyridines	86-102	nuclear receptor subfamily 3 group C member 2	Homo sapiens	36-62
20650892-2	2010	We screened for novel nonsteroidal compounds and identified MR antagonists derived from the chemical class of dihydropyridines.	Dihydropyridines	110-126	nuclear receptor subfamily 3 group C member 2	Homo sapiens	60-62
20167851-3	2010	We have previously shown that dihydropyridines selectively modulate Th2 cell functions.	Dihydropyridines	30-46	heart and neural crest derivatives expressed 2	Mus musculus	68-71
20167851-4	2010	OBJECTIVES: Because dihydropyridines bind to and modulate voltage-dependent calcium (Ca(v)1) channel in excitable cells, we aimed at showing that Th2 cells selectively express functional Ca(v)1-related channels, the inhibition of which may prevent asthma.	Dihydropyridines	20-36	caveolin 1, caveolae protein	Mus musculus	85-91
20167851-4	2010	OBJECTIVES: Because dihydropyridines bind to and modulate voltage-dependent calcium (Ca(v)1) channel in excitable cells, we aimed at showing that Th2 cells selectively express functional Ca(v)1-related channels, the inhibition of which may prevent asthma.	Dihydropyridines	20-36	heart and neural crest derivatives expressed 2	Mus musculus	146-149
20167851-4	2010	OBJECTIVES: Because dihydropyridines bind to and modulate voltage-dependent calcium (Ca(v)1) channel in excitable cells, we aimed at showing that Th2 cells selectively express functional Ca(v)1-related channels, the inhibition of which may prevent asthma.	Dihydropyridines	20-36	caveolin 1, caveolae protein	Mus musculus	187-193
19401195-0	2009	Five different profiles of dihydropyridines in blocking T-type Ca(2+) channel subtypes (Ca(v)3.1 (alpha(1G)), Ca(v)3.2 (alpha(1H)), and Ca(v)3.3 (alpha(1I))) expressed in Xenopus oocytes.	Dihydropyridines	27-43	calcium channel, voltage-dependent, T type, alpha 1G subunit L homeolog	Xenopus laevis	88-96
20382537-5	2010	In an attempt to identify potent and selective antagonists of Ca(V)1.3 channels, 124 dihydropyridines (4-substituted-1,4-dihydropyridine-3,5-dicarboxylic diesters) were synthesized.	Dihydropyridines	85-101	calcium voltage-gated channel subunit alpha1 D	Homo sapiens	62-70
19401195-0	2009	Five different profiles of dihydropyridines in blocking T-type Ca(2+) channel subtypes (Ca(v)3.1 (alpha(1G)), Ca(v)3.2 (alpha(1H)), and Ca(v)3.3 (alpha(1I))) expressed in Xenopus oocytes.	Dihydropyridines	27-43	caveolin 3, gene 2 S homeolog	Xenopus laevis	110-118
19401195-0	2009	Five different profiles of dihydropyridines in blocking T-type Ca(2+) channel subtypes (Ca(v)3.1 (alpha(1G)), Ca(v)3.2 (alpha(1H)), and Ca(v)3.3 (alpha(1I))) expressed in Xenopus oocytes.	Dihydropyridines	27-43	calcium channel, voltage-dependent, T type, alpha 1I subunit L homeolog	Xenopus laevis	136-144
19007592-1	2008	OBJECTIVES: Because of the known CYP3A4 inhibition by calcium-channel blockers (CCBs), we hypothesized that there might be a drug-drug interaction between clopidogrel and dihydropyridines in patients with coronary artery disease.	Dihydropyridines	171-187	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	33-39
18974361-4	2009	The goal of this study was to identify compounds that block the Ca(v)3.2 T-type channel with high affinity, focusing on two classes of compounds: phenylalkylamines (e.g., mibefradil) and dihydropyridines (e.g., efonidipine).	Dihydropyridines	187-203	immunoglobulin lambda variable 7-43	Homo sapiens	64-72
17651721-4	2007	Previously a low sensitivity of the Ca(v)1.3 subtype towards dihydropyridines has been demonstrated.	Dihydropyridines	61-77	calcium channel, voltage-dependent, L type, alpha 1D subunit	Mus musculus	36-44
18221369-1	2008	Dihydropyridines can affect L-type calcium channels (CaV1) as either agonists or antagonists.	Dihydropyridines	0-16	caveolin 1	Homo sapiens	53-57
18250364-4	2008	These dihydropyridines varied in the extent of their effect on mineralocorticoid receptor, with nimodipine and felodipine the most potent and amlodipine the least.	Dihydropyridines	6-22	nuclear receptor subfamily 3, group C, member 2	Rattus norvegicus	63-89
18250364-6	2008	These dihydropyridines compete with aldosterone for binding and block aldosterone-induced coactivator recruitment to mineralocorticoid receptor.	Dihydropyridines	6-22	nuclear receptor subfamily 3, group C, member 2	Rattus norvegicus	117-143
18250364-9	2008	Molecular modeling indicates that dihydropyridines dock into the ligand binding domain of mineralocorticoid receptor in a consensus pose that partially overlaps with steroidal mineralocorticoid receptor antagonists.	Dihydropyridines	34-50	nuclear receptor subfamily 3, group C, member 2	Rattus norvegicus	90-116
18250364-9	2008	Molecular modeling indicates that dihydropyridines dock into the ligand binding domain of mineralocorticoid receptor in a consensus pose that partially overlaps with steroidal mineralocorticoid receptor antagonists.	Dihydropyridines	34-50	nuclear receptor subfamily 3, group C, member 2	Rattus norvegicus	176-202
17954368-1	2007	BACKGROUND: Angiotensin II-mediated increases in sympathetic activity may contribute to smaller blood-pressure decreases in response to dihydropyridines in young versus older hypertensive patients.	Dihydropyridines	136-152	angiotensinogen	Homo sapiens	12-26
17610813-2	2007	demonstrates that blockade of these channels by dihydropyridines re-establishes the pacemaking driven by sodium and HCN channels found in juvenile SN.	Dihydropyridines	48-64	metastasis associated lung adenocarcinoma transcript 1	Homo sapiens	116-119
17512522-3	2007	Therefore, we have studied the inhibitory effects of dihydropyridines on both human equilibrative nucleoside transporters, hENT-1 and hENT-2, which are the major transporters mediating nucleoside transport in most tissues.	Dihydropyridines	53-69	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	123-129
17512522-3	2007	Therefore, we have studied the inhibitory effects of dihydropyridines on both human equilibrative nucleoside transporters, hENT-1 and hENT-2, which are the major transporters mediating nucleoside transport in most tissues.	Dihydropyridines	53-69	solute carrier family 29 member 2	Homo sapiens	134-140
17512522-4	2007	Among the dihydropyridines tested, nimodipine proved to be the most potent inhibitor of hENT-1, with an IC(50) value of 60+/-31 muM, whereas nifedipine, nicardipine, nitrendipine, and felodipine exhibited 100-fold less effective inhibitory activity.	Dihydropyridines	10-26	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	88-94
17512522-10	2007	We conclude that dihydropyridines are non-competitive inhibitors of hENT-1 and hENT-2, probably working through reversible interactions with the allosteric sites.	Dihydropyridines	17-33	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	68-74
17512522-10	2007	We conclude that dihydropyridines are non-competitive inhibitors of hENT-1 and hENT-2, probably working through reversible interactions with the allosteric sites.	Dihydropyridines	17-33	solute carrier family 29 member 2	Homo sapiens	79-85